Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies
Antibody Therapeutics · 16.09.2026
DOI: 10.1093/abt/tbag049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibody Therapeutics, online erschienen am 16.09.2026. Verfasst von Chaitanya Tondepu und 8 weiteren Autor:innen. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Astellas.
Abstract (Originalsprache)
Background
Chimeric antigen receptor (CAR) T cells targeting B cell maturation antigen (BCMA) have demonstrated considerable therapeutic advantages in treating multiple myeloma (MM) patients, increasing progression-free survival and overall survival compared to standard-of-care regimens. However, many patients still experience cytokine release syndrome, immune cell–associated neurotoxicity syndrome, long-term cytopenias, B cell aplasia, and hypogammaglobulinemia, with the majority ultimately facing relapse within 5 years of treatment.
Methods
A dual-component system comprising convertibleCAR (cCAR) T cells and MicAbodies (MAs), which bridge the cancer target to cCAR T cells to elicit a cytotoxic response, was used to assess platform flexibility by formatting MAs and evaluating their binding affinity, hydrophobicity, polyreactivity, cytotoxicity against MM cell lines, and susceptibility to inhibition by soluble BCMA (sBCMA). In vivo efficacy of the lead molecule was also assessed in a disseminated MM tumor model.
Results
The study generated a panel of 15 MAs from three clones, revealing that clones B8 and B3 exhibited superior cytotoxicity and greater retained activity in the presence of sBCMA compared to clone B4, particularly in specific formats. In vivo administration of B8 LCm with cCAR T cells reduced tumor burden relative to untreated and untransduced T-cell control groups in a BCMA+ multiple myeloma model.
Conclusion
The modularity and flexibility of the cCAR platform, along with the optimization of MA formats and clones, have the potential to enhance functional tuning of CAR T cell therapies, which may support improved efficacy and safety.
Förderung
- Astellas
Zitieren
APA
Tondepu, C., Wong, A., Wong, C., Krishnaswamy, S., Michaels, S., Chu, M. L., Kim, K. C., Starling, G. C., & Kearney, A. (2026). Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies. Antibody Therapeutics. https://doi.org/10.1093/abt/tbag049
Vancouver
Tondepu C, Wong A, Wong C, Krishnaswamy S, Michaels S, Chu ML, et al. Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies. Antibody Therapeutics. 2026. doi:10.1093/abt/tbag049
BibTeX
@article{Tondepu2026,
author = {Tondepu, Chaitanya and Wong, Andrew and Wong, Clifford and Krishnaswamy, Senthilkumar and Michaels, Shawnya and Chu, Matthew Ling-Hon and Kim, Kaman C and Starling, Gary C and Kearney, Alper},
title = {Dual-component CAR T cell therapy: targeting BCMA with convertible CAR and MicAbodies},
journal = {Antibody Therapeutics},
year = {2026},
doi = {10.1093/abt/tbag049}
}
EUVIMED